Site icon pharmaceutical daily

New Clinical Trials Report on Glioblastoma Pipeline Insights – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Glioblastoma Pipeline Insight 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.


This report offers comprehensive insights about more than 190 companies and over 200 pipeline drugs in the Glioblastoma pipeline landscape. It covers the drug profiles in both clinical and nonclinical stages, therapeutics assessment based on product type, stage, route of administration, and molecule type, as well as highlights inactive pipeline products in this area.

Glioblastoma: Understanding

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) in adults, and its prognosis remains poor despite advancements in diagnostics and therapies. GBMs exhibit a complex network of various molecular and genetic aberrations, resulting in significant changes in major signaling pathways. These aggressive, fast-growing tumors are lethal due to extensive dispersion throughout the brain, making maximal surgical resection challenging. GBM is the most common and aggressive primary brain tumor in humans, accounting for a significant proportion of all primary brain tumor cases.

Report Highlights

The report presents a detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and discovery. It covers clinical trial details, pharmacological action, agreements and collaborations, and the latest news and press releases related to Glioblastoma.

Glioblastoma Emerging Drugs

The report covers several emerging drugs in different stages of development, including:

  1. Enzastaurin: Denovo BioPharma – An orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways, studied in various solid and hematological tumor types. It has received Orphan Drug Designation for GBM.

  2. Marizomib: Bristol-Myers Squibb – A next-generation naturally-occurring salinosporamide, a potential antineoplastic agent, currently in Phase III for the treatment of GBM.

  3. VT1021: Vigeo Therapeutics – A first-in-class dual modulating compound that blocks the CD47 immune checkpoint and activates CD36, with potential to convert “cold” tumors to “hot” tumors. It is advancing into Phase II/III for solid tumors, including GBM.

  4. ONC201: Chimerix, Inc. – An orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist, under development for GBM.

Glioblastoma: Therapeutic Assessment

The report provides insights into different therapeutic candidates in phase II, I, preclinical, and discovery stages, along with collaborations, acquisitions, mergers, licensing activities, and emerging drug assessment.

Key Players and Key Products

The report covers key companies developing therapies for Glioblastoma and their respective products. Some of the key players covered include:

This report is a valuable resource for researchers, clinicians, and industry stakeholders seeking to understand the current treatment landscape and emerging therapies for Glioblastoma.

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/jd9123

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version